Payment overview · 2025
General Payments
$124.49
7 reported records · 7 companies
Healthcare provider profile · identity verified
Robert Bernard Mann, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORENCE, AL · NPI 1548371347
Verified facts
What the public records show
CMS Open Payments records show Robert Bernard Mann, MD received $124.49 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 291 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.83 | 19.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.17 | 15.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.63 | 15.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.88 | 13.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.77 | 12.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.16 | 12.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.05 | 11.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.49 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
291 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 616 | 172 |
| Pantoprazole Sodium | Pantoprazole Sodium | 590 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 503 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 488 | 137 |
| Omeprazole | Omeprazole | 399 | 111 |
| Losartan Potassium | Losartan Potassium | 394 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 342 | 107 |
| Eliquis | Apixaban | 291 | 60 |
| Tramadol Hcl | Tramadol Hcl | 291 | 70 |
| Azithromycin | Azithromycin | 274 | 151 |
| Tamsulosin Hcl | Tamsulosin Hcl | 274 | 67 |
| Furosemide | Furosemide | 269 | 87 |
| Gabapentin | Gabapentin | 260 | 69 |
| Metformin Hcl | Metformin Hcl | 232 | 67 |
| Potassium Chloride | Potassium Chloride | 225 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 61 |
| Montelukast Sodium | Montelukast Sodium | 208 | 53 |
| Spironolactone | Spironolactone | 204 | 55 |
| Mounjaro | Tirzepatide | 192 | 32 |
| Allopurinol | Allopurinol | 181 | 58 |
| Sertraline Hcl | Sertraline Hcl | 181 | 47 |
| Irbesartan | Irbesartan | 177 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 174 | 50 |
| Methylprednisolone | Methylprednisolone | 167 | 116 |
| Labetalol Hcl | Labetalol Hcl | 165 | 46 |
| Simvastatin | Simvastatin | 159 | 46 |
| Lisinopril | Lisinopril | 155 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 33 |
| Prednisone | Prednisone | 149 | 81 |
| Meloxicam | Meloxicam | 145 | 57 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 133 | 29 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 130 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 16 |
| Ezetimibe | Ezetimibe | 113 | 32 |
| Mirtazapine | Mirtazapine | 112 | 39 |
| Memantine Hcl | Memantine Hcl | 110 | 20 |
| Carvedilol | Carvedilol | 101 | 29 |
| Farxiga | Dapagliflozin Propanediol | 101 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 32 |
| Clonidine Hcl | Clonidine Hcl | 99 | 31 |
| Famotidine | Famotidine | 97 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 94 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 22 |
| Buspirone Hcl | Buspirone Hcl | 91 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 90 | 25 |
| Meclizine Hcl | Meclizine Hcl | 89 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 50 |
| Finasteride | Finasteride | 87 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 25 |
| Glimepiride | Glimepiride | 84 | 24 |
| Glipizide | Glipizide | 84 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 30 |
| Donepezil Hcl | Donepezil Hcl | 82 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 22 |
| Metformin Hcl Er | Metformin Hcl | 80 | 24 |
| Alprazolam | Alprazolam | 79 | 17 |
| Ozempic | Semaglutide | 79 | 14 |
| Jardiance | Empagliflozin | 77 | 15 |
| Trazodone Hcl | Trazodone Hcl | 77 | 27 |
| Xarelto | Rivaroxaban | 75 | 13 |
| Lorazepam | Lorazepam | 73 | 13 |
| Warfarin Sodium | Warfarin Sodium | 73 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 71 | 23 |
| Clonazepam | Clonazepam | 70 | 11 |
| Atenolol | Atenolol | 69 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 19 |
| Januvia | Sitagliptin Phosphate | 67 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 14 |
| Temazepam | Temazepam | 65 | suppressed |
| Valsartan | Valsartan | 58 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | suppressed |
| Ramipril | Ramipril | 57 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 13 |
| Sucralfate | Sucralfate | 56 | 16 |
| Synthroid | Levothyroxine Sodium | 56 | 11 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 55 | 12 |
| Glipizide Er | Glipizide | 49 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 13 |
| Methocarbamol | Methocarbamol | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 16 |
| Celecoxib | Celecoxib | 45 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 29 |
| Alendronate Sodium | Alendronate Sodium | 42 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Creon | Lipase/Protease/Amylase | 41 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 37 | 13 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Nystatin | Nystatin | 37 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 15 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 13 |
| Estradiol | Estradiol | 32 | 11 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 20 |
| Terbinafine Hcl | Terbinafine Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | 12 |
| Clotrimazole | Clotrimazole | 22 | 18 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Dulera | Mometasone/Formoterol | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Promethazine Hcl | Promethazine Hcl | 21 | 11 |
| Cefdinir | Cefdinir | 20 | 17 |
| Fluconazole | Fluconazole | 20 | 16 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Nadolol | Nadolol | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Budesonide Ec | Budesonide | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Chlordiazepoxide-Amitriptyline | Amitriptyline/Chlordiazepoxide | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.49 · 7 records | Novo Nordisk Inc | FARXIGA, JARDIANCE, Kerendia, NEXLETOL, Ozempic, PAXLOVID, REXULTI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error